
Gilead Sciences company profile
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and sells medicines, with a focus on virology, oncology and inflammation. Its commercial portfolio includes more than 25 therapies, among them HIV treatments and prevention products such as Biktarvy, Descovy, Genvoya and Yeztugo; hepatitis C and B treatments Epclusa and Vemlidy; cell therapies Yescarta and Tecartus; the breast cancer treatment Trodelvy; and AmBisome and Veklury. In the U.S., most products are sold through wholesale channels, with a large share of gross sales historically going to three wholesalers. Outside the U.S., products are marketed through commercial teams, third-party distributors and corporate partners. The company operates in more than 35 countries, with headquarters in Foster City, California, and manufacturing facilities in California, Ireland and Canada.
A summary of the business section of the company's latest annual report, filed 24 Feb 2026.
Company facts
| Ticker | GILD · Nasdaq |
|---|
| Sector | Biotechnology |
|---|
| Industry | Biotechnology |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 882095 |
|---|
| Latest annual report | 10-K, filed 24 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Daniel P. O’Day | Chairman & CEO · Director | 2.0M · < 1% | Option exercise, 5 Nov 2026 |
|---|
| Johanna Mercier | Chief Comm & Corp Aff Officer | 634K · < 1% | Sale under a 10b5-1 plan, 15 Oct 2026 |
|---|
| Andrew D. Dickinson | Chief Financial Officer | 376K · < 1% | Sale under a 10b5-1 plan, 15 Oct 2026 |
|---|
| Jacqueline K. Barton, Ph.D. | Director | 122K · < 1% | Grant or award, 30 Apr 2026 |
|---|
| Kelly A. Kramer | Director | 120K · < 1% | Sale under a 10b5-1 plan, 28 Nov 2025 |
|---|
| Harish Manwani | Director | 103K · < 1% | Grant or award, 30 Apr 2026 |
|---|
| Sandra J. Horning, M.D. | Director | 84.8K · < 1% | Grant or award, 30 Apr 2026 |
|---|
| Javier J. Rodriguez | Director | 81.0K · < 1% | Grant or award, 30 Apr 2026 |
|---|
| Anthony Welters | Director | 79.6K · < 1% | Sale under a 10b5-1 plan, 26 Aug 2026 |
|---|
| Deborah H. Telman | EVP, Corporate Affairs & GC | 59.4K · < 1% | Option exercise, 12 Nov 2025 |
|---|
| Jeffrey A. Bluestone, Ph.D. | Director | 55.7K · < 1% | Option exercise, 20 Aug 2026 |
|---|
| Dietmar Berger, M.D., Ph.D. | Chief Medical Officer | 29.5K · < 1% | Shares withheld for tax, 10 Sep 2026 |
|---|
| Ted W. Love, M.D. | Director | 26.8K · < 1% | Grant or award, 30 Apr 2026 |
|---|
| Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | — | Sale under a 10b5-1 plan, 6 Nov 2026 |
|---|
| Burkhart Erin | SVP, Controllership | — | Shares withheld for tax, 22 Sep 2026 |
|---|
| Wilfong Diane E. | Interim Corp Controller & CAO | — | Shares withheld for tax, 10 Sep 2025 |
|---|
| Patterson Sandra | SVP, Controllership | — | Shares withheld for tax, 10 Mar 2025 |
|---|
| Parsey Merdad | Chief Medical Officer | — | Shares withheld for tax, 10 Dec 2024 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
GILD in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.